LogicBio Therapeutics Announces Collaboration with Takeda to Develop New Genome Editing Candidate LB-301 for the Treatment of Crigler-Najjar Syndrome

Stock Information for LogicBio Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About LogicBio Therapeutics Inc.

LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BTRS, JVA, AKUS, LOGC
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Myovant Sciences Ltd. (NYSE - MYOV), ForgeRock, Inc. (NYSE - FORG), SeaSpine Holdings Corporation (Nasdaq - SPNE), LogicBio Therapeutics, Inc. (Nasdaq - LOGC), Coffe
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SMBC, BTRS, LOGC, RCOR
SHAREHOLDER ALERT: Weiss Law Reminds LOGC, POSH, AERC, and BTRS Shareholders About Its Ongoing Investigations
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) ForgeRock, Inc. (NYSE - FORG), SeaSpine Holdings Corporation (Nasdaq - SPNE), LogicBio Therapeutics, Inc. (Nasdaq - LOGC), Coffee Holding Co., Inc. (Nasdaq - JVA)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AAWW, LOGC, RFP, PBFX, RNWK
LOGICBIO® THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LogicBio® Therapeutics, Inc. - LOGC

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.